arrow
T

Thorsten Annecke

University of Cologne
H指数:23
被引数:2,457

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Glycocalyx-Shedding and Inflammatory Reactions Occur Yet Do Not Predict Complications Resulting from an Esophagectomy in an Accelerated Recovery After Surgery Program

Glycocalyx-Shedding和炎症反应虽会出现,但并不能预测加速康复外科程序中因食管切除术所导致的并发症

2025-08-280
OA
No one-size-fits-all approach: Retrospective analysis of efficacy and safety of serum concentrations of continuously administered vancomycin in critically ill adults reveals different target serum concentrations depending on disease severity

非一刀切的方法:对连续输注万古霉素在危重成人中血清浓度的疗效和安全性的回顾性分析显示,根据疾病严重程度存在不同的目标血清浓度。

2025-06-200
OA
S3 guideline: Diagnosis and treatment of epidermal necrolysis(Stevens-Johnson syndrome and toxic epidermal necrolysis) -Part 2: Supportive therapy of EN in the acute and post-acute stages

S3指南: 表皮坏死松解症 (stevens-johnson综合征和中毒性表皮坏死松解症) 的诊断和治疗.第2部分: 急性和急性后阶段EN的支持治疗

2024-11-070
OAAI
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 2: Supportive therapy of EN in the acute and post-acute stages
2024-10-170
OAAI
S3-Leitlinie: Diagnostik und Therapie der epidermalen Nekrolyse (Stevens-Johnson-Syndrom und toxisch epidermale Nekrolyse) - Teil 1: Diagnostik, initiales Management und immunmodulierende Systemtherapie

S3指南:表皮坏死(Stevens-Johnson综合征和中毒性表皮坏死)的诊断与治疗——第1部分:诊断、初始管理和免疫调节系统性治疗

2024-10-110
OAAI
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 1: Diagnosis, initial management, and immunomodulating systemic therapy
2024-09-230
OAAI
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial (vol 48, pg 311, 2022)
2022-03-182
OAAI
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial

基于治疗药物监测的哌拉西林/他唑巴坦剂量优化对脓毒症相关器官功能障碍影响的随机对照试验

2022-02-01107
OAAI